-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical network on March 8th, the nationwide collection, the latest news came out
Special procurement with volume, already on the way
According to the WeChat public account "Fengyun Medicine Talk" news, the one and a half day and a half-long gathering meeting has come to an end on March 5.
Everyone paid great attention to the three key points of the conference: special quantity procurement, national procurement renewal, and national procurement rules.
Some news was also reported.
Everyone paid great attention to the three key points of the conference: special quantity procurement, national procurement renewal, and national procurement rules.
Some news was also reported.
According to the "Opinions on Promoting the Normalized and Institutionalized Development of Centralized and Volume Procurement of Drugs , State Council Fa [2021] No.
2" officially issued by the General Office of the State Council on January 28 , the clinical efficacy will be "in accordance with the reasonable price difference relationship.
Combining different dosage forms, specifications, packaging, and purchases of similar drugs with the same generic name in the same route of administration to promote competition.
Explore the merger of different generic drugs with similar indications or functions and indications to carry out centralized procurement.
"
2" officially issued by the General Office of the State Council on January 28 , the clinical efficacy will be "in accordance with the reasonable price difference relationship.
Combining different dosage forms, specifications, packaging, and purchases of similar drugs with the same generic name in the same route of administration to promote competition.
Explore the merger of different generic drugs with similar indications or functions and indications to carry out centralized procurement.
"
At the State Council’s regular policy briefing in January this year, regarding the content of "the normalization and institutionalization of centralized drug procurement," the person in charge said: "According to the No.
2 document issued by the State Council and the exploration situation, Biosimilar drugs are included in centralized procurement, including large varieties of Chinese patent medicines.
This is an institutional requirement, but the rules are more optimized, more targeted, and the quality is more in line with the attributes of the drug itself.
From our country, The quality standards of biosimilars are relatively high globally, higher than those of some Western countries.
In two sentences, one is that there is no doubt that it is included in centralized procurement; the other is that quality must be our priority consideration, and the rules must be more in line with the market.
Claim.
"
2 document issued by the State Council and the exploration situation, Biosimilar drugs are included in centralized procurement, including large varieties of Chinese patent medicines.
This is an institutional requirement, but the rules are more optimized, more targeted, and the quality is more in line with the attributes of the drug itself.
From our country, The quality standards of biosimilars are relatively high globally, higher than those of some Western countries.
In two sentences, one is that there is no doubt that it is included in centralized procurement; the other is that quality must be our priority consideration, and the rules must be more in line with the market.
Claim.
"
It can be seen that special procurement with volume may become a key focus of the work in 2021.
Some analysts say that insulin may become the first batch of "specialized quantity-collection" products, and the special quantity-based procurement of Chinese patent medicines and other biological agents may be temporarily released later.
Some analysts say that insulin may become the first batch of "specialized quantity-collection" products, and the special quantity-based procurement of Chinese patent medicines and other biological agents may be temporarily released later.
As we all know, the amount of insulin used in clinical practice is very huge (second only to oral preparations of acarbose), and there are a large population of diabetic patients in my country.
For the first time, it was included in the Wuhan special centralized procurement attempt.
Many people believe that special insulin procurement is already on the way, and it may be involved as soon as 2021.
For the first time, it was included in the Wuhan special centralized procurement attempt.
Many people believe that special insulin procurement is already on the way, and it may be involved as soon as 2021.
As for the inclusion of proprietary Chinese medicines in centralized procurement, most people said that they would not advance so quickly.
The main reason is that proprietary Chinese medicines are different from Western medicines with relatively single effects.
Most Chinese medicine products can only be defined by treatment location or treatment field, and there is no clear generic name.
Therefore, the definition of a unified standard for proprietary Chinese medicines will be more complicated, and it is difficult to use the model of Western medicine to purchase in quantities.
The main reason is that proprietary Chinese medicines are different from Western medicines with relatively single effects.
Most Chinese medicine products can only be defined by treatment location or treatment field, and there is no clear generic name.
Therefore, the definition of a unified standard for proprietary Chinese medicines will be more complicated, and it is difficult to use the model of Western medicine to purchase in quantities.
Renewal work is a top priority
For each batch of national procurement, the follow-up will face the problem of contract renewal.
It is also a general trend that the renewed varieties will compete again and accelerate the price reduction.
It is also a general trend that the renewed varieties will compete again and accelerate the price reduction.
How to renew the contract for nationally sourced varieties? There are two methods that are more discussed in the industry.
One method is to directly renew the contract of the original selected variety, but if there are new over-rated manufacturers for that variety during the period, it seems unfair to renew the new over-rated manufacturers directly.
Another method is to re-negotiate the qualified companies on the basis of not higher than the original selected price, and the lower quotation can be renewed.
One method is to directly renew the contract of the original selected variety, but if there are new over-rated manufacturers for that variety during the period, it seems unfair to renew the new over-rated manufacturers directly.
Another method is to re-negotiate the qualified companies on the basis of not higher than the original selected price, and the lower quotation can be renewed.
Regarding the rules of contract renewal, it is currently being explored everywhere.
At the same time, the contract period after the renewal is also the focus of the industry.
Because of the renewal time, how long the selected companies occupy the market, and how long the non-selected companies lose the market.
For example, in the renewal of the 4+7 expansion in Hubei, it stipulates that “for the renewal of the original selected company, the pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement cycle is in principle one year, and the procurement agreement shall be signed according to regulations; if the bidding produces a new selected company, the procurement cycle is in principle two years ".
The industry believes that these new regulations will bring market opportunities for new over-assessed companies.
At the same time, the contract period after the renewal is also the focus of the industry.
Because of the renewal time, how long the selected companies occupy the market, and how long the non-selected companies lose the market.
For example, in the renewal of the 4+7 expansion in Hubei, it stipulates that “for the renewal of the original selected company, the pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement cycle is in principle one year, and the procurement agreement shall be signed according to regulations; if the bidding produces a new selected company, the procurement cycle is in principle two years ".
The industry believes that these new regulations will bring market opportunities for new over-assessed companies.
Centralized procurement and renewal time summary
(Drawing: Fengyun Medicine Talk)
Although the fifth batch of national centralized procurement and special volume procurement in 2021 are the focus of the industry, for pharmaceutical companies, the renewal of centralized procurement is also a top priority.
Especially for companies that have not won the bid or have been newly evaluated, if they can seize the first opportunity in the work of renewing the bid, it will be an opportunity for the development of the product market, and it will also be a reshuffle and impact on the original competitive landscape of centralized procurement.
Especially for companies that have not won the bid or have been newly evaluated, if they can seize the first opportunity in the work of renewing the bid, it will be an opportunity for the development of the product market, and it will also be a reshuffle and impact on the original competitive landscape of centralized procurement.
Medical network on March 8th, the nationwide collection, the latest news came out
Special procurement with volume, already on the way
According to the WeChat public account "Fengyun Medicine Talk" news, the one and a half day and a half-long gathering meeting has come to an end on March 5.
Everyone paid great attention to the three key points of the conference: special quantity procurement, national procurement renewal, and national procurement rules.
Some news was also reported.
Everyone paid great attention to the three key points of the conference: special quantity procurement, national procurement renewal, and national procurement rules.
Some news was also reported.
According to the "Opinions on Promoting the Normalized and Institutionalized Development of Centralized and Volume Procurement of Drugs , State Council Fa [2021] No.
2" officially issued by the General Office of the State Council on January 28 , the clinical efficacy will be "in accordance with the reasonable price difference relationship.
Combining different dosage forms, specifications, packaging, and purchases of similar drugs with the same generic name in the same route of administration to promote competition.
Explore the merger of different generic drugs with similar indications or functions and indications to carry out centralized procurement.
"
2" officially issued by the General Office of the State Council on January 28 , the clinical efficacy will be "in accordance with the reasonable price difference relationship.
Combining different dosage forms, specifications, packaging, and purchases of similar drugs with the same generic name in the same route of administration to promote competition.
Explore the merger of different generic drugs with similar indications or functions and indications to carry out centralized procurement.
"
At the State Council’s regular policy briefing in January this year, regarding the content of "the normalization and institutionalization of centralized drug procurement," the person in charge said: "According to the No.
2 document issued by the State Council and the exploration situation, Biosimilar drugs are included in centralized procurement, including large varieties of Chinese patent medicines.
This is an institutional requirement, but the rules are more optimized, more targeted, and the quality is more in line with the attributes of the drug itself.
From our country, The quality standards of biosimilars are relatively high globally, higher than those of some Western countries.
In two sentences, one is that there is no doubt that it is included in centralized procurement; the other is that quality must be our priority consideration, and the rules must be more in line with the market.
Claim.
"
2 document issued by the State Council and the exploration situation, Biosimilar drugs are included in centralized procurement, including large varieties of Chinese patent medicines.
This is an institutional requirement, but the rules are more optimized, more targeted, and the quality is more in line with the attributes of the drug itself.
From our country, The quality standards of biosimilars are relatively high globally, higher than those of some Western countries.
In two sentences, one is that there is no doubt that it is included in centralized procurement; the other is that quality must be our priority consideration, and the rules must be more in line with the market.
Claim.
"
It can be seen that special procurement with volume may become a key focus of the work in 2021.
Some analysts say that insulin may become the first batch of "specialized quantity-collection" products, and the special quantity-based procurement of Chinese patent medicines and other biological agents may be temporarily released later.
Some analysts say that insulin may become the first batch of "specialized quantity-collection" products, and the special quantity-based procurement of Chinese patent medicines and other biological agents may be temporarily released later.
As we all know, the amount of insulin used in clinical practice is very huge (second only to oral preparations of acarbose), and there are a large population of diabetic patients in my country.
For the first time, it was included in the Wuhan special centralized procurement attempt.
Many people believe that special insulin procurement is already on the way, and it may be involved as soon as 2021.
For the first time, it was included in the Wuhan special centralized procurement attempt.
Many people believe that special insulin procurement is already on the way, and it may be involved as soon as 2021.
As for the inclusion of proprietary Chinese medicines in centralized procurement, most people said that they would not advance so quickly.
The main reason is that proprietary Chinese medicines are different from Western medicines with relatively single effects.
Most Chinese medicine products can only be defined by treatment location or treatment field, and there is no clear generic name.
Therefore, the definition of a unified standard for proprietary Chinese medicines will be more complicated, and it is difficult to use the model of Western medicine to purchase in quantities.
The main reason is that proprietary Chinese medicines are different from Western medicines with relatively single effects.
Most Chinese medicine products can only be defined by treatment location or treatment field, and there is no clear generic name.
Therefore, the definition of a unified standard for proprietary Chinese medicines will be more complicated, and it is difficult to use the model of Western medicine to purchase in quantities.
Renewal work is a top priority
For each batch of national procurement, the follow-up will face the problem of contract renewal.
It is also a general trend that the renewed varieties will compete again and accelerate the price reduction.
It is also a general trend that the renewed varieties will compete again and accelerate the price reduction.
How to renew the contract for nationally sourced varieties? There are two methods that are more discussed in the industry.
One method is to directly renew the contract of the original selected variety, but if there are new over-rated manufacturers for that variety during the period, it seems unfair to renew the new over-rated manufacturers directly.
Another method is to re-negotiate the qualified companies on the basis of not higher than the original selected price, and the lower quotation can be renewed.
One method is to directly renew the contract of the original selected variety, but if there are new over-rated manufacturers for that variety during the period, it seems unfair to renew the new over-rated manufacturers directly.
Another method is to re-negotiate the qualified companies on the basis of not higher than the original selected price, and the lower quotation can be renewed.
Regarding the rules of contract renewal, it is currently being explored everywhere.
At the same time, the contract period after the renewal is also the focus of the industry.
Because of the renewal time, how long the selected companies occupy the market, and how long the non-selected companies lose the market.
For example, in the renewal of the 4+7 expansion in Hubei, it stipulates that “for the renewal of the original selected company, the pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement cycle is in principle one year, and the procurement agreement shall be signed according to regulations; if the bidding produces a new selected company, the procurement cycle is in principle two years ".
The industry believes that these new regulations will bring market opportunities for new over-assessed companies.
At the same time, the contract period after the renewal is also the focus of the industry.
Because of the renewal time, how long the selected companies occupy the market, and how long the non-selected companies lose the market.
For example, in the renewal of the 4+7 expansion in Hubei, it stipulates that “for the renewal of the original selected company, the pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement cycle is in principle one year, and the procurement agreement shall be signed according to regulations; if the bidding produces a new selected company, the procurement cycle is in principle two years ".
The industry believes that these new regulations will bring market opportunities for new over-assessed companies.
Centralized procurement and renewal time summary
(Drawing: Fengyun Medicine Talk)
Although the fifth batch of national centralized procurement and special volume procurement in 2021 are the focus of the industry, for pharmaceutical companies, the renewal of centralized procurement is also a top priority.
Especially for companies that have not won the bid or have been newly evaluated, if they can seize the first opportunity in the work of renewing the bid, it will be an opportunity for the development of the product market, and it will also be a reshuffle and impact on the original competitive landscape of centralized procurement.
Especially for companies that have not won the bid or have been newly evaluated, if they can seize the first opportunity in the work of renewing the bid, it will be an opportunity for the development of the product market, and it will also be a reshuffle and impact on the original competitive landscape of centralized procurement.
Medical network on March 8th, the nationwide collection, the latest news came out
Special procurement with volume, already on the way
Special procurement with volume, already on the way According to the WeChat public account "Fengyun Medicine Talk" news, the one and a half day and a half-long gathering meeting has come to an end on March 5.
Everyone paid great attention to the three key points of the conference: special quantity procurement, national procurement renewal, and national procurement rules.
Some news was also reported.
Everyone paid great attention to the three key points of the conference: special quantity procurement, national procurement renewal, and national procurement rules.
Some news was also reported.
According to the "Opinions on Promoting the Normalized and Institutionalized Development of Centralized and Volume Procurement of Drugs , State Council Fa [2021] No.
2" officially issued by the General Office of the State Council on January 28 , the clinical efficacy will be "in accordance with the reasonable price difference relationship.
Combining different dosage forms, specifications, packaging, and purchases of similar drugs with the same generic name in the same route of administration to promote competition.
Explore the merger of different generic drugs with similar indications or functions and indications to carry out centralized procurement.
"
Medicine, medicine, medicine2" officially issued by the General Office of the State Council on January 28 , the clinical efficacy will be "in accordance with the reasonable price difference relationship.
Combining different dosage forms, specifications, packaging, and purchases of similar drugs with the same generic name in the same route of administration to promote competition.
Explore the merger of different generic drugs with similar indications or functions and indications to carry out centralized procurement.
"
At the State Council’s regular policy briefing in January this year, regarding the content of "the normalization and institutionalization of centralized drug procurement," the person in charge said: "According to the No.
2 document issued by the State Council and the exploration situation, Biosimilar drugs are included in centralized procurement, including large varieties of Chinese patent medicines.
This is an institutional requirement, but the rules are more optimized, more targeted, and the quality is more in line with the attributes of the drug itself.
From our country, The quality standards of biosimilars are relatively high globally, higher than those of some Western countries.
In two sentences, one is that there is no doubt that it is included in centralized procurement; the other is that quality must be our priority consideration, and the rules must be more in line with the market.
Claim.
"
Standard Standard Standard2 document issued by the State Council and the exploration situation, Biosimilar drugs are included in centralized procurement, including large varieties of Chinese patent medicines.
This is an institutional requirement, but the rules are more optimized, more targeted, and the quality is more in line with the attributes of the drug itself.
From our country, The quality standards of biosimilars are relatively high globally, higher than those of some Western countries.
In two sentences, one is that there is no doubt that it is included in centralized procurement; the other is that quality must be our priority consideration, and the rules must be more in line with the market.
Claim.
"
It can be seen that special procurement with volume may become a key focus of the work in 2021.
Some analysts say that insulin may become the first batch of "specialized quantity-collection" products, and the special quantity-based procurement of Chinese patent medicines and other biological agents may be temporarily released later.
Some analysts say that insulin may become the first batch of "specialized quantity-collection" products, and the special quantity-based procurement of Chinese patent medicines and other biological agents may be temporarily released later.
As we all know, the amount of insulin used in clinical practice is very huge (second only to oral preparations of acarbose), and there are a large population of diabetic patients in my country.
For the first time, it was included in the Wuhan special centralized procurement attempt.
Many people believe that special insulin procurement is already on the way, and it may be involved as soon as 2021.
For the first time, it was included in the Wuhan special centralized procurement attempt.
Many people believe that special insulin procurement is already on the way, and it may be involved as soon as 2021.
As for the inclusion of proprietary Chinese medicines in centralized procurement, most people said that they would not advance so quickly.
The main reason is that proprietary Chinese medicines are different from Western medicines with relatively single effects.
Most Chinese medicine products can only be defined by treatment location or treatment field, and there is no clear generic name.
Therefore, the definition of a unified standard for proprietary Chinese medicines will be more complicated, and it is difficult to use the model of Western medicine to purchase in quantities.
The main reason is that proprietary Chinese medicines are different from Western medicines with relatively single effects.
Most Chinese medicine products can only be defined by treatment location or treatment field, and there is no clear generic name.
Therefore, the definition of a unified standard for proprietary Chinese medicines will be more complicated, and it is difficult to use the model of Western medicine to purchase in quantities.
Renewal work is a top priority
Renewal work is a top priority For each batch of national procurement, the follow-up will face the problem of contract renewal.
It is also a general trend that the renewed varieties will compete again and accelerate the price reduction.
It is also a general trend that the renewed varieties will compete again and accelerate the price reduction.
How to renew the contract for nationally sourced varieties? There are two methods that are more discussed in the industry.
One method is to directly renew the contract of the original selected variety, but if there are new over-rated manufacturers for that variety during the period, it seems unfair to renew the new over-rated manufacturers directly.
Another method is to re-negotiate the qualified companies on the basis of not higher than the original selected price, and the lower quotation can be renewed.
Enterprise business enterpriseOne method is to directly renew the contract of the original selected variety, but if there are new over-rated manufacturers for that variety during the period, it seems unfair to renew the new over-rated manufacturers directly.
Another method is to re-negotiate the qualified companies on the basis of not higher than the original selected price, and the lower quotation can be renewed.
Regarding the rules of contract renewal, it is currently being explored everywhere.
At the same time, the contract period after the renewal is also the focus of the industry.
Because of the renewal time, how long the selected companies occupy the market, and how long the non-selected companies lose the market.
For example, in the renewal of the 4+7 expansion in Hubei, it stipulates that “for the renewal of the original selected company, the pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement cycle is in principle one year, and the procurement agreement shall be signed according to regulations; if the bidding produces a new selected company, the procurement cycle is in principle two years ".
The industry believes that these new regulations will bring market opportunities for new over-assessed companies.
pharmnet. At the same time, the contract period after the renewal is also the focus of the industry.
Because of the renewal time, how long the selected companies occupy the market, and how long the non-selected companies lose the market.
For example, in the renewal of the 4+7 expansion in Hubei, it stipulates that “for the renewal of the original selected company, the pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement cycle is in principle one year, and the procurement agreement shall be signed according to regulations; if the bidding produces a new selected company, the procurement cycle is in principle two years ".
The industry believes that these new regulations will bring market opportunities for new over-assessed companies.
com.
cn/news/yyzb/" target="_blank">Procurementpharmnet.
com.
cn/news/yyzb/" target="_blank"> Procurement Procurement
Centralized procurement and renewal time summary
(Drawing: Fengyun Medicine Talk)
Although the fifth batch of national centralized procurement and special volume procurement in 2021 are the focus of the industry, for pharmaceutical companies, the renewal of centralized procurement is also a top priority.
Especially for companies that have not won the bid or have been newly evaluated, if they can seize the first opportunity in the work of renewing the bid, it will be an opportunity for the development of the product market, and it will also be a reshuffle and impact on the original competitive landscape of centralized procurement.
Especially for companies that have not won the bid or have been newly evaluated, if they can seize the first opportunity in the work of renewing the bid, it will be an opportunity for the development of the product market, and it will also be a reshuffle and impact on the original competitive landscape of centralized procurement.
